Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Wilson’s Disease Market Outlook

The Wilson’s disease market size was valued at USD 1457.5 million in 2023, driven by the rising research and development activities in drug development across the major markets. The market is expected to grow at a CAGR of 3.2% during the forecast period of 2024-2032, with the values likely to rise from USD 1498.9 million in 2024 to USD 1926.6 million by 2032.

Wilson’s Disease: Introduction

Wilson’s disease is a rare genetic condition that leads to copper level build up in several body organs, particularly, brain, eyes, and liver. Major symptoms include yellowing of skin and eyes, occurrence of golden-brown or copper-colored rings around the irises of the eyes (Kayser-Fleischer rings), along with tiredness, loss of appetite, fluid buildup in legs and stomach area. It is treated via medications and surgery in case of extreme cases.

Wilson’s Disease Market Analysis

Wilson’s disease has been treated via medications that constitute chelating agents (medicines that remove copper from the body). Penicillamine (Cupramine, Depen) and trientine (Syprine) are two commonly prescribed medications that help remove excess copper from the body. Zinc is another frequent medication that blocks copper absorption in intestines.

Wilson’s disease market demand is further fueled by the rising advancements in gene therapies. In September 2023, UC Davis Health researchers infused the first ever gene therapy in an affected patient. The clinical trial for Wilson’s disease called CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment. It is an adeno-associated virus gene therapy that restores the function of ATP7B, that improves copper metabolism and distribution in the body.

With increasing technical advances in the medical ecosystem, scientists have been looking into finding ways to effectively devise better diagnostic methods that identify the illness at an early stage. Similarly, a better understanding of human physiology, along with hefty investments made by public and private institutions, is also poised to fuel the Wilson’s disease market value in upcoming years.

Wilson’s Disease Market Segmentation

Market Breakup by Diagnosis Method

  • Blood and Urine Test
  • Eye Exam
  • Biopsy
  • Genetic Testing

Market Breakup by Treatment Type

  • Medications
    • Penicillamine
    • Trientine Dihydrocholoride
    • Trientine Tetrahydrochoride
  • Surgery

Market Breakup by Mode of Administration

  • Injectable
  • Oral
  • Others

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

Wilson’s Disease Market Overview

The United States is anticipated to dominate the Wilson’s disease market share in the forecast period. The market size can be accredited to increasing mergers and acquisitions in the region to foster better inventions for patient outcomes. Several companies are growing their product portfolios to meet the high demand for patient therapeutics.

Europe is another significant market with a robust healthcare and research infrastructure that aids market growth. The presence of prominent research and academic institutions along with leading healthcare companies also fuels market value.

Wilson’s Disease Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Teva Pharmaceutical
  • ANI Pharmaceuticals
  • Bausch Health
  • DR. REDDY’S LABORATORIES LTD
  • Breckenridge Pharmaceutical, Inc.
  • Par pharmaceutical
  • Lupin
  • Panacea Biotech Ltd
  • Apotex
  • Navinta LLC
  • Amneal Pharmaceuticals LLC.
  • Meda Pharmaceuticals
  • Ipsen Pharma
  • Noblepharma Co., Ltd.
  • Wilson Therapeutics AB

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diagnosis Method
  • Treatment Type
  • Mode of Administration
  • End User 
  • Distribution Channel 
  • Region
Breakup by Diagnosis Method
  • Blood and Urine Test
  • Eye Exam
  • Biopsy
  • Genetic Testing
Breakup by Treatment Type
  • Medications
  • Surgery
Breakup by Mode of Administration
  • Injectable
  • Oral
  • Others
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Teva Pharmaceutical
  • ANI Pharmaceuticals
  • Bausch Health
  • DR. REDDY’S LABORATORIES LTD
  • Breckenridge Pharmaceutical, Inc.
  • Par pharmaceutical
  • Lupin
  • Panacea Biotech Ltd
  • Apotex
  • Navinta LLC
  • Amneal Pharmaceuticals LLC.
  • Meda Pharmaceuticals
  • Ipsen Pharma
  • Noblepharma Co., Ltd.
  • Wilson Therapeutics AB

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 1457.5 million in 2023, driven by increasing research and development activities in drug development across the major markets.

The market is anticipated to grow at a CAGR of 3.2% during the forecast period of 2024-2032, likely to reach a market value of USD 1926.6 million by 2032.

The market demand is driven by the rising expenditure on medical research and development to develop better treatment methods for the disease.

The major market trend involves the application of gene therapies as a treatment alternative. In September 2023, results from a clinical trial called, CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment for Wilson’s disease.

The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom. 

The diagnosis methods include blood and urine test, eye exam, biopsy, and genetic testing.

The treatment types can be categorised into medications (penicillamine trientine dihydrocholoride and trientine tetrahydrochoride) and surgery.

The modes of administration can be divided into injectable and oral, among others.

The end users can be divided into hospitals, homecare, and specialty clinics, among other others.

The distribution channels can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.

Key players involved in the market are Teva Pharmaceutical, ANI Pharmaceuticals, Bausch Health, DR. REDDY’S LABORATORIES LTD, Breckenridge Pharmaceutical, Inc., Par pharmaceutical, Lupin, Panacea Biotech Ltd., Apotex, Navinta LLC, Amneal Pharmaceuticals LLC., Meda Pharmaceuticals, Ipsen Pharma, Noblepharma Co., Ltd., and Wilson’s Therapeutics AB.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124